home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410b.zip
/
M94A0277.TXT
< prev
next >
Wrap
Text File
|
1994-10-08
|
3KB
|
44 lines
Document 0277
DOCN M94A0277
TI Current therapy of dermatophytosis.
DT 9412
AU Degreef HJ; DeDoncker PR; Department of Dermatology, UZ Saint-Rafael
Catholic University; Leuven, Belgium.
SO J Am Acad Dermatol. 1994 Sep;31(3 Pt 2):S25-30. Unique Identifier :
AIDSLINE MED/94358244
AB In the past dermatophytes were treated with topical agents or, in the
case of more recalcitrant or extensive disease, with oral antifungals
(griseofulvin or ketoconazole). Topical therapies may be effective in
many cases, but they have limitations. They may be viewed as
inconvenient by the patient, thereby affecting compliance. Therapy with
early oral antifungals entails long treatment periods until complete
cure is obtained. For ketoconazole rare but serious side effects can
occur, particularly with prolonged use. Griseofulvin is still the drug
of choice for the treatment of tinea capitis of the Microsporum type. In
recent years a few new antimycotic agents have been developed for
systemic therapy of superficial fungal infections. Itraconazole is a
broad-spectrum triazole. Fluconazole belongs to the same chemical class
and was used mainly in systemic yeast infections and mucosal candidosis.
Terbinafine is an allylamine and has been found to be effective and safe
in brief therapy of dermatophyte infections. Short-duration therapy of
most dermatophyte infections is also possible with itraconazole. The
high and specific activity against the causative agents, together with
their pharmacokinetic properties, explains the good results obtained
with these new drugs and their improved safety profile. Their mode of
action, pharmacokinetics, and treatment schedules will be discussed.
DE Acquired Immunodeficiency Syndrome/COMPLICATIONS Administration, Oral
Administration, Topical Allylamine/PHARMACOLOGY/THERAPEUTIC USE
Antifungal Agents/PHARMACOLOGY/*THERAPEUTIC USE
Dermatomycoses/COMPLICATIONS/*DRUG THERAPY Drug Administration Schedule
Fluconazole/PHARMACOLOGY/THERAPEUTIC USE
Griseofulvin/PHARMACOLOGY/THERAPEUTIC USE Human
Itraconazole/PHARMACOLOGY/THERAPEUTIC USE
Ketoconazole/PHARMACOLOGY/THERAPEUTIC USE
Morpholines/PHARMACOLOGY/THERAPEUTIC USE Time Factors
Tolnaftate/PHARMACOLOGY/THERAPEUTIC USE JOURNAL ARTICLE REVIEW
REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).